Innovative gelatin-based micelles with AS1411 aptamer targeting and reduction responsiveness for doxorubicin delivery in tumor therapy - 27/04/24
, Lei Zhang b, ⁎ Abstract |
Herein, we constructed innovative reduction-sensitive and targeted gelatin-based micelles for doxorubicin (DOX) delivery in tumor therapy. AS1411 aptamer-modified gelatin-ss-tocopherol succinate (AGSST) and the control GSST without AS1411 modification were synthesized and characterized. Antitumor drug DOX-containing AGSST (AGSST-D) and GSST-D nanoparticles were prepared, and their shapes were almost spherical. Reduction-responsive characteristics of DOX release in vitro were revealed in AGSST-D and GSST-D. Compared with non-targeted GSST-D, AGSST-D demonstrated better intracellular uptake and stronger cytotoxicity against nucleolin-overexpressed A549 cells. Importantly, AGSST-D micelles showed more effective killing activity in A549-bearing mice than GSST-D and DOX⋅HCl. It was revealed that AGSST-D micelles had no obvious systemic toxicity. Overall, AGSST micelles would have the potential to be an effective drug carrier for targeted tumor therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
We developed reduction-sensitive, targeted gelatin micelles for doxorubicin delivery in cancer therapy, showing enhanced uptake and effectiveness in A549 cells and mice, with minimal systemic toxicity.
We developed reduction-sensitive, targeted gelatin micelles for doxorubicin delivery in cancer therapy, showing enhanced uptake and effectiveness in A549 cells and mice, with minimal systemic toxicity.Le texte complet de cet article est disponible en PDF.
Highlights |
• | Reduction-sensitive and targeted gelatin-based micelle for doxorubicin (D) delivery. |
• | AS1411 aptamer-modified gelatin-ss-tocopherol succinate (AGSST). |
• | AGSST-D enhances uptake and cytotoxicity against nucleolin-overexpressed A549 cells. |
• | AGSST-D effectively inhibits tumor growth in A549 mouse models. |
Keywords : AS1411 aptamer, Targeted delivery, Reduction sensitive, Doxorubicin, Gelatin, Micelles
Plan
Vol 174
Article 116446- mai 2024 Retour au numéro
Article précédent
- Tolperisone hydrochloride improves motor functions in Parkinson’s disease via MMP-9 inhibition and by downregulating p38 MAPK and ERK1/2 signaling cascade
- Bushra Zaman, Irona Mostafa, Tazree Hassan, Shamim Ahmed, Nusrat Jahan Ikbal Esha, Fowzia Afsana Chowdhury, Tory Bosu, Humayra Noor Chowdhury, Anup Mallick, MM Shanjid Islam, Ayesha Sharmin, Kabir M. Uddin, Md. Mainul Hossain, Mahbubur Rahman
- Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson’s disease
- Jae-Bong Kim, Soo-Jeong Kim, Minyoung So, Dong-Kyu Kim, Hye Rin Noh, Beom Jin Kim, Yu Ree Choi, Doyoon Kim, Heejung Koo, Taeyong Kim, Hyun Goo Woo, Sang Myun Park
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?